TMA and Immunohistochemistry

Tissue microarrays (TMA) are effective tools for the histological analysis of tumors to discover biomarkers and characterize the mode of action of new drug candidates. They are also used for the analysis of target protein expression in a large set of tumors of different origin simultaneously to identify suitable mouse models for anticancer drug efficacy studies.

Reaction Biology’s TMA is a paraffin block which contains tumor cores made from our syngeneic mouse models available for efficacy testing at our in vivo pharmacology unit.

The tumor tissue microarray empowers to:

  • Select the best tumor model based on target expression
  • Ensure the immune population needed for your mode of action is present in the tumor model for efficacy studies
  • Confirm the immune-modulatory effects in animals treated with your drug candidate
  • Find biomarkers predicting the drug response in tumor models

A TMA can also be newly designed and made for endpoint analysis of an animal study.
Get in contact today with our scientists to discuss options to make use of our TMA service.

Caught in the act.

A TMA enables the comparison of various tumor models in regards of their histology, target expression, and immune cell infiltration.

Target proteins or immune markers are visualized on a cellular level understanding their location in stromal or tumoral tissue.

Options to use Reaction Biology’s TMA for your cancer drug research project?

Our TMA service can be used in four ways:

  • Histology images of our syngeneic tumor models aid an informed decision for a tumor model for efficacy drug testing
  • Slides of our TMA can be stained with antibodies according to client needs in collaboration with an external partner lab.
  • Slides of the TMA can be shipped to clients for in-house processing.
  • De novo TMA’s can be created with tumors harvested in animal studies for in-depth endpoint analysis.

Please reach out to learn more about our tissue microarray and how it can help you decide for the most suitable tumor model for your drug discovery project.

Immunohistochemistry for in-depth analysis of the mode of action of your immunotherapeutics

Immunohistochemistry enables the identification of immune cells in tumor tissue and also offers the opportunity to quantify target expression in the tumors. The advantage of IHC compared to flow cytometry is the ability to visualize the localization of the target cell population. For example, you can see if immune cells that infiltrate the tumor are stuck in the stromal part of the tumor or actually migrate into the tumor tissue. IHC can be performed with several markers on one slide to co-localize immune populations to answer specific functional questions about the effects of immunotherapeutics.

Therefore, IHC is usually used as a second line pharmacodynamic readout performed when flow cytometry or multiplex MSD have yielded promising results.

IHC for endpoint analysis or TMA analysis is performed by a partner lab specializing in histology work for high quality results. Please contact us today to discuss the use of IHC for animal study endpoint readouts.